Oxford Nanopore Technologies PLC ONT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX200.00
- Day Range
- GBX200.20–210.20
- 52-Week Range
- GBX95.61–238.80
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 978.45M
- Market Cap
- GBX204.69B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Oxford Nanopore Technologies PLC is involved in researching, developing, manufacturing and commercializing deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that provides rich data, is fast, accessible and easy to use, and which allows the real-time analysis of DNA or RNA. It has developed and brought to market a new generation molecular sensing platform based on nanopores. The first application is DNA/RNA sequencing and the platform is also being developed for the analysis of proteins and metabolites. It operates in single segment of providing products and services related to the sale and use of its nanopore-based sensing technology. Geographically its operations are spread across EMES, AMR, and APAC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,314
- Website
- https://www.nanoporetech.com
Valuation
|
Metric
|
ONT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.37 |
Price/Sales | 8.23 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ONT
|
|---|---|
Quick Ratio | 2.73 |
Current Ratio | 3.52 |
Interest Coverage | −42.45 |
Quick Ratio
ONT
Profitability
|
Metric
|
ONT
|
|---|---|
Return on Assets (Normalized) | −16.51% |
Return on Equity (Normalized) | −42.19% |
Return on Invested Capital (Normalized) | −21.03% |
Return on Assets
ONT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|NY<?s#v | LOCK|w>nw | $127B | |||
| Moderna Inc
MRNA
| LOCK|v#&X?d | LOCK|>w | $91B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|W>Zqbkf | LOCK|yHws | $81B | |||
| argenx SE ADR
ARGX
| LOCK|p>^h&K& | LOCK|j# | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Klt&tbt | LOCK|HBC | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&FmMH%< | LOCK|$<dT | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|RkG>v^l | LOCK|h>BV | $27B | |||
| Incyte Corp
INCY
| LOCK|<gPf>!g | LOCK|!?> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|pwX$j> | LOCK|y% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|l!#c^j> | LOCK|r<< | $14B |
United States